Bone-targeted therapies to reduce skeletal morbidity in prostate cancer.

about

Bone-targeted therapies to reduce skeletal morbidity in prostate cancer.

Item

http://www.wikidata.org/entity/Q52649233

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Bone-targeted therapies to reduce skeletal morbidity in prostate cancer.

@en

Bone-targeted therapies to reduce skeletal morbidity in prostate cancer.

@nl

type

Item

label

Bone-targeted therapies to reduce skeletal morbidity in prostate cancer.

@en

Bone-targeted therapies to reduce skeletal morbidity in prostate cancer.

@nl

prefLabel

Bone-targeted therapies to reduce skeletal morbidity in prostate cancer.

@en

Bone-targeted therapies to reduce skeletal morbidity in prostate cancer.

@nl

P1476

Bone-targeted therapies to reduce skeletal morbidity in prostate cancer.

@en

P2093

Neeraj Agarwal

http://www.w3.org/2001/XMLSchema#string

Tanya B Dorff

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International

P2860

Latent bone metastasis in breast cancer tied to Src-dependent survival signals

Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial

Interactions of human prostatic epithelial cells with bone marrow endothelium: binding and invasion

Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation

Osteoclast differentiation and activation

Alpha emitter radium-223 and survival in metastatic prostate cancer

Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment.

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

P304

215-220

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.4103/AJA.AJA_12_18

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29553053

http://www.w3.org/2001/XMLSchema#string

P921

bone neoplasm

inorganic compound

organophosphorus compound

mechanism of action

P932

5952474

http://www.w3.org/2001/XMLSchema#string